• Prescribing Information
  • Medical Information
  • Ordering & Inventory

    Multiple channels for convenient ordering

    Pfizer TruSupport gives you a variety of ways to order, track, and pay for TRUMENBA

      • Go to pfizerprime.com, the fastest, easiest way to order TRUMENBA. All in 1 place, open anytime and anywhere
      • Order by phone 1-800-666-7248
      • Order with your wholesaler

      Pfizer Sales Representatives also have you covered

      Keeping track of your inventory can be time-consuming. That’s why Pfizer Sales Representatives have Inventory Management Tools on their iPads to help record, evaluate, and accurately forecast your stock for you. Ask a Pfizer Sales Representative about how this tool can benefit your practice.

      Visit the Pfizer Prime website to learn more about ordering TRUMENBA

      Learn more

      Administering TRUMENBA1

          • Before administering, shake syringe vigorously to ensure that a homogenous white suspension of TRUMENBA is obtained
          • TRUMENBA should be administered intramuscularly using a sterile needle attached to the supplied prefilled syringe. The preferred site for injection is the deltoid muscle of the upper arm
          • Do not mix TRUMENBA with any other vaccine in the same syringe

            How to store TRUMENBA1

                • Upon receipt, store TRUMENBA refrigerated at 2°C to 8°C (36°F to 46°F)
                • Store syringes in the refrigerator horizontally (laying flat on the shelf)

                  Reference:
                  1. Trumenba [prescribing information]. Philadelphia, PA: Pfizer Inc; 2019.

                  Support & Services

                  • Welcome to TruSupport
                  • Ordering & Inventory
                  • Coverage & Reimbursement
                  • Patient Adherence

                  Coverage & Reimbursement with TruSupport

                  Streamlines the processes of confirming your patient's coverage for TRUMENBA

                  Learn how Pfizer streamlines

                  Patient Adherence

                  Tools to help your patients start and stay on track with the TRUMENBA series

                  Learn about these tools

                  Indication

                  • Trumenba is a vaccine indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. Trumenba is approved for use in individuals 10 through 25 years of age
                  • The effectiveness of the two-dose schedule of Trumenba against diverse N meningitidis serogroup B strains has not been confirmed
                  • Severe allergic reaction after a previous dose of Trumenba is a contraindication
                  • Some individuals with altered immunocompetence may have reduced immune responses to Trumenba
                  • Persons with certain complement deficiencies and persons receiving treatment that inhibits terminal complement activation (for example, eculizumab) are at increased risk for invasive disease caused by Neisseria meningitidis serogroup B even if they develop antibodies following vaccination with Trumenba
                  • As with any vaccine, vaccination with Trumenba may not protect all vaccine recipients against N meningitidis serogroup B infections
                  • Syncope (fainting) can occur in association with administration of injectable vaccines, including Trumenba. Procedures should be in place to avoid injury from fainting
                  • In clinical studies, the most common solicited adverse reactions in adolescents and young adults were pain at injection site (≥85%), fatigue (≥60%), headache (≥55%), and muscle pain (≥35%). Nausea was reported in up to 24% of adolescents in early phase studies
                  • Sufficient data are not available on the safety and effectiveness of using Trumenba and other meningococcal group B vaccines interchangeably to complete the vaccination series
                  • Safety and effectiveness have not been established in pregnant women
                  • Trumenba is a vaccine indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. Trumenba is approved for use in individuals 10 through 25 years of age
                  • The effectiveness of the two-dose schedule of Trumenba against diverse N meningitidis serogroup B strains has not been confirmed

                  Please see full Prescribing Information.​​​​​​​